Table 1 Patient and tumor characteristics
| Â | N (%) |
|---|---|
Age at operation (years)a | 62 (32–91) |
Tumor size (mm)a | 17.5 (5–100) |
Nodal status | |
N0 | 124 (70.1) |
N1–3 | 53 (29.9) |
TNM-stage | |
I | 85 (48.0) |
II | 80 (45.2) |
III | 12 (6.8) |
Estrogen receptor status | |
Negative | 26 (14.7) |
Positive | 151 (85.3) |
Progesterone receptor status | |
Negative | 47 (26.6) |
Positive | 130 (73.4) |
Her2/Neu status (FISH) | |
Negative | 154 (87.0) |
Positive | 23 (13.0) |
Ki-67 (%)b | 18 (1-95) |
Low-proliferative | 94 (53.1) |
High-proliferative | 82 (46.3) |
Nottingham histological grade | |
I | 38 (21.5) |
II | 84 (47.5) |
III | 55 (31.1) |
Molecular subtype | |
Luminal A | 88 (49.7) |
Luminal B | 46 (26.0) |
Luminal B Her2/Neu-overexpressing | 17 (9.6) |
Non-luminal Her2/Neu-overexpressing | 6 (3.4) |
Basal-like | 20 (11.3) |
Lymphovascular invasion (LVI) | |
Yes | 24 (13.6) |
No | 133 (75.1) |
Adjuvant radiotherapy | |
Breast or chest wall only | 110 (62.2) |
Locoregional | 33 (18.6) |
Adjuvant chemotherapy | |
Anthracyclines | 53 (29.9) |
Taxane-based | 30 (16.9) |
Other | 1 (0.0) |
Adjuvant endocrine therapy | 151 (85.3) |
Anti-Her2/Neu therapy (trastuzumab) | 19 (10.7) |